RXRX Stock Recursion Pharmaceuticals, Inc.
Today’s call · RXRX
All live ideas →5 of 6 technical checks lean bearish
RXRX is in a downtrend, momentum soft. $2.5 is the level overhead; $2 the first support below.
- A close below $2 on rising volume (breakdown).
- A bounce to $2.5 that fails (entry near resistance).
The brief
All readings
Levels that matter
Compare with…
Recursion Pharmaceuticals (RXRX) stock analysis, November 20, 2026: bearish outlook with high conviction
Recursion Pharmaceuticals (RXRX) closed at $2.51 on November 20, 2026, after a 7.7% daily drop that pushed the price below the key $2.5 round support level. The daily trend is in line with a weekly downtrend, and the stock is lagging both the S&P 500 and the healthcare sector (XLV) over the past 50 days. The balance of evidence points to a bearish stance for the next two to six weeks, with a high conviction that the price will test the $2.0 support if the downside breakout math holds.
Why it matters
The recent price action reflects a continuation of a broader weakness in the biotechnology segment of healthcare. RXRX fell 21.2% over the past five days, while the S&P 500 slipped 8.1% and XLV dropped 5.7% in the same period. The stock’s underperformance versus the sector (-15.5% relative) shows that the move is not merely a market‑wide pullback but also a company‑specific deterioration. No material news was released in the last trading session, so the market reaction appears to be a mechanical continuation of the downtrend rather than a response to new fundamentals.
Investors had already priced in a weakening of the weekly trend, as the price sits below its 40‑week average and the 50‑day simple moving average ($3.7204) is well above the current level. The RSI at 31.7 signals that the stock is approaching oversold territory, yet the volume is 18.8% below its 20‑day average, indicating a lack of buying pressure to reverse the slide. The recent peak of $4.35 on October 28 represents a 42.3% drop to today’s price, underscoring the steep correction that has unfolded.
Analyst consensus remains a “buy” with a mean price target of $6.77, but that target is 62.9% above the current price, suggesting a valuation gap that has not been bridged by recent performance. The spread between the current price and the mean target highlights the disconnect between analyst optimism and market reality, especially given the stock’s lagging performance versus both the broader market and its sector.
While some market participants argue that the stock is oversold and poised for a rebound, the quantitative evidence—particularly the breakout math and the structural resistance at $2.785—counters that view. The downside breakout level of a daily close below $2.5 is already breached, and the stop at $2.87 is anchored to a swing‑zone level plus a fraction of the 14‑day ATR. The math yields a target of $2.0 with a reward‑to‑risk of 1.4, falling short of the 3‑to‑1 ratio that would make the move attractive for many traders. Those who see a short‑term bounce must contend with the fact that the weekly trend remains down and that the price is still holding below the swing‑zone resistance at $2.785.
What the evidence says
On the long‑term horizon, the thesis that RXRX is in a downtrend remains intact. The price is below both its 40‑week average and the 200‑day SMA ($3.4451), and the recent decline from the October peak has erased nearly half of the 52‑week range. The structural swing‑zone resistance at $2.785 continues to hold, indicating that sellers are still active on any rally attempts.
For the next two to six weeks, the balance of evidence leans negative with high conviction. The assessment cites three of four conviction points: the daily trend mirrors the weekly downtrend, the stock lags the S&P 500 by 25.9% over 50 days, and it lags XLV by 33.4% over the same span. The breakout math points to a downside move toward $2.0, and the reward‑to‑risk does not meet the 3‑to‑1 threshold, reinforcing the bearish reading.
The strongest case against this reading would be a rapid reversal in sector momentum or a surprise positive catalyst that lifts XLV and the broader market, narrowing the relative lag. Even if XLV were to post a sudden 10% gain, the stock’s own 5‑day decline of 21.2% would still dominate the picture, leaving the conviction largely unchanged.
Levels that matter
The price is currently holding above the swing‑zone resistance at $2.785, a level where sellers have historically stepped in during rallies. A close above $2.85, another swing‑zone marker, would signal the end of the weekly downtrend, as the assessment notes that the trend would end above that level.
The downside breakout level is a daily close below the round $2.5 support. The stop is set at $2.87, derived from the $2.785 swing‑zone plus a quarter of the 14‑day ATR (0.32). The math projects a target of $2.0, a round support, with a reward‑to‑risk of 1.4. Because the reward‑to‑risk does not reach 3‑to‑1, the price would need to fall to roughly $1.75 to achieve that ratio, a level not currently on the chart.
What would change the picture
A weekly close above $2.85 would alter the current outlook, as the assessment defines that level as the trigger for ending the weekly downtrend. A significant earnings surprise—such as a materially better‑than‑expected revenue or pipeline update on November 2—could also shift sentiment, even though the price rule itself is purely technical.
What to watch
- Next earnings release on November 2; the earnings per share figure will be the key metric.
- Sector events that could move XLV, such as FDA approvals or major biotech mergers, which would affect RXRX’s relative performance.
- Analyst valuation spread: the consensus “buy” with a mean target of $6.77 remains far above the current price, a 62.9% discount that signals a large valuation gap.